GSE45255
Breat cancer dataset (Genome Biol 2013, 139 patients)
| SUBTYPE | SUBTYPE2 | SUBTYPE3 | DSS time | adjuvant treated? (0=no, 1=yes) | characteristics: endocrine? (0=no, 1=yes) | chemo? (0=no, 1=yes) | dfs event (defined as any type of recurrence or death from breast cancer) | dfs time | dmfs event (defined as distant metastasis or death from breast cancer) | dmfs time | dss event (defined as death from breast cancer) | er status | her2 status | histological grade | histology | ln status | patient age | pgr status | size (mm) | treatment type | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSM1100037 | ER+ | ER+ | ER+ | 6.17 | 1 | 1 | 1 | 0 | 6.17 | 0 | 6.17 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 41 | PgR+ | 20 | Tam+ACx4 cycles |
| GSM1100038 | HER2+ | HER2+ | ER-/HER2+ | 1.13 | 1 | 0 | 1 | 1 | 1.13 | 1 | 1.13 | 0 | ER- | He+ | G2 | invasive ductal carcinoma | LN+ | 62 | PgR- | 30 | ACx4 cycles |
| GSM1100039 | ER+ | ER+ | ER+ | 4.29 | 1 | 1 | 0 | 0 | 4.29 | 0 | 4.29 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 69 | PgR+ | 30 | Tamoxifen |
| GSM1100040 | ER+ | ER+ | ER+ | 6.04 | 1 | 1 | 0 | 0 | 5.88 | 0 | 5.88 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 69 | PgR+ | 35 | Tamoxifen |
| GSM1100041 | HER2+ | ER+ | ER+/HER2+ | 2.63 | 1 | 1 | 1 | 0 | 2.63 | 0 | 2.63 | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN- | 40 | PgR+ | 25 | Tam+CMFx6 cycles |
| GSM1100042 | HER2+ | ER+ | ER+/HER2+ | 6.25 | 1 | 1 | 0 | 0 | 6.25 | 0 | 6.25 | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN- | 69 | PgR- | 25 | Tamoxifen |
| GSM1100043 | HER2+ | HER2+ | ER-/HER2+ | 2.25 | 1 | 0 | 1 | 1 | 2.00 | 1 | 2.00 | 0 | ER- | He+ | G2 | invasive ductal carcinoma | LN+ | 54 | PgR- | 60 | ACx4 cycles |
| GSM1100044 | HER2+ | ER+ | ER+/HER2+ | 5.63 | NaN | NaN | NaN | 0 | 5.63 | 0 | 5.63 | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN- | 48 | PgR+ | 20 | NaN |
| GSM1100045 | HER2+ | HER2+ | ER-/HER2+ | 4.08 | 0 | 0 | 0 | 0 | 4.04 | 0 | 4.04 | 0 | ER- | He+ | G2 | invasive ductal carcinoma | LN- | 46 | PgR- | 15 | none |
| GSM1100046 | ER+ | ER+ | ER+ | 6.00 | 1 | 1 | 0 | 0 | 6.00 | 0 | 6.00 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 53 | PgR- | 18 | Tamoxifen |
| GSM1100047 | ER+ | ER+ | ER+ | 5.79 | 1 | 0 | 1 | 0 | 5.79 | 0 | 5.79 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 52 | PgR+ | 18 | CMF |
| GSM1100048 | NaN | NaN | NaN | 5.83 | 1 | 0 | 1 | 0 | 5.83 | 0 | 5.83 | 0 | ER- | He- | G2 | invasive ductal carcinoma | LN+ | 50 | PgR+ | 25 | CAF |
| GSM1100049 | NaN | NaN | NaN | 5.92 | 1 | 0 | 1 | 0 | 5.75 | 0 | 5.75 | 0 | ER- | He- | G2 | invasive ductal carcinoma | LN+ | 53 | PgR+ | 22 | CMF |
| GSM1100050 | HER2+ | ER+ | ER+/HER2+ | 5.58 | 1 | 1 | 0 | 0 | 5.58 | 0 | 5.58 | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN- | 77 | PgR- | 35 | Tamoxifen |
| GSM1100051 | ER+ | ER+ | ER+ | 6.33 | 1 | 1 | 1 | 0 | 6.33 | 0 | 6.33 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 60 | PgR+ | 20 | Tam+CMFx6 cycles |
| GSM1100052 | HER2+ | ER+ | ER+/HER2+ | NaN | 1 | 1 | 1 | NaN | NaN | NaN | NaN | NaN | ER+ | He+ | G2 | invasive ductal carcinoma | LN+ | 51 | PgR- | 25 | Tam+ACx8;taxol |
| GSM1100053 | ER+ | ER+ | ER+ | 5.00 | 1 | 0 | 1 | 0 | 5.00 | 0 | 5.00 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN+ | 69 | PgR+ | 25 | CAF |
| GSM1100054 | HER2+ | ER+ | ER+/HER2+ | 5.25 | 1 | 1 | 1 | 0 | 5.25 | 0 | 5.25 | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN+ | 49 | PgR+ | 23 | Tam+CAFx6 cycles |
| GSM1100055 | ER+ | ER+ | ER+ | 3.08 | 1 | 0 | 1 | 1 | 0.04 | 1 | 0.04 | 1 | ER+ | He- | G2 | invasive lobular carcinoma | LN- | 48 | PgR- | 15 | anastrozole;taxol |
| GSM1100056 | HER2+ | HER2+ | ER-/HER2+ | 5.42 | 1 | 1 | 0 | 1 | 0.92 | 0 | 0.67 | 0 | ER- | He+ | G2 | invasive ductal carcinoma | LN+ | 75 | PgR+ | 40 | Tamoxifen |
| GSM1100057 | HER2+ | HER2+ | ER-/HER2+ | 2.83 | 0 | 0 | 0 | 1 | 2.83 | 1 | 2.83 | 0 | ER- | He+ | G2 | invasive ductal carcinoma | LN- | 67 | PgR- | 25 | none |
| GSM1100058 | ER+ | ER+ | ER+ | 4.58 | 0 | 0 | 0 | 1 | 1.25 | 0 | 0.67 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 55 | PgR+ | 15 | none |
| GSM1100059 | NaN | NaN | NaN | 4.67 | 1 | 1 | 1 | 0 | 4.67 | 0 | 4.67 | 0 | ER- | He- | G2 | invasive ductal carcinoma | LN- | 35 | PgR+ | 40 | Tam+ACx4 cycles |
| GSM1100060 | HER2+ | ER+ | ER+/HER2+ | 5.67 | 1 | 0 | 1 | 0 | 5.67 | 0 | 5.67 | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN+ | 46 | PgR+ | 30 | CAF |
| GSM1100061 | ER+ | ER+ | ER+ | 4.67 | 1 | 0 | 1 | 0 | 4.67 | 0 | 4.67 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 44 | PgR+ | 35 | CMF |
| GSM1100062 | ER+ | ER+ | ER+ | 5.17 | 1 | 0 | 1 | 0 | 5.17 | 0 | 5.17 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN+ | 40 | PgR+ | 23 | CAF |
| GSM1100063 | HER2+ | ER+ | ER+/HER2+ | 4.75 | 1 | 1 | 0 | 0 | 4.75 | 0 | 4.75 | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN- | 57 | PgR+ | 21 | Tamoxifen |
| GSM1100064 | ER+ | ER+ | ER+ | 4.92 | 1 | 1 | 0 | 0 | 4.92 | 0 | 4.92 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN+ | 55 | PgR+ | 19 | Tamoxifen |
| GSM1100065 | HER2+ | ER+ | ER+/HER2+ | 0.42 | 0 | 0 | 0 | 0 | 0.42 | 0 | 0.42 | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN+ | 44 | PgR+ | 24 | none |
| GSM1100066 | HER2+ | ER+ | ER+/HER2+ | 1.75 | 1 | 1 | 1 | 1 | 1.67 | 1 | 1.67 | 1 | ER+ | He+ | G2 | invasive ductal carcinoma | LN+ | 46 | PgR- | 60 | Tam+CAFx2 cycles |
| GSM1100067 | ER+ | ER+ | ER+ | 4.50 | NaN | NaN | NaN | 0 | 4.50 | 0 | 4.50 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN+ | 42 | PgR- | 30 | NaN |
| GSM1100068 | ER+ | ER+ | ER+ | 4.88 | 1 | 1 | 1 | 0 | 4.88 | 0 | 4.88 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 46 | PgR+ | 15 | Tam+CMFx6 cycles |
| GSM1100069 | ER+ | ER+ | ER+ | 4.92 | 1 | 1 | 0 | 0 | 4.83 | 0 | 4.83 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN+ | 73 | PgR+ | 20 | Tamoxifen |
| GSM1100070 | NaN | NaN | NaN | 4.50 | NaN | NaN | NaN | 0 | 4.00 | 0 | 4.00 | 0 | ER- | He- | G2 | invasive ductal and lobular carcinoma | LN+ | 46 | PgR+ | 40 | NaN |
| GSM1100071 | HER2+ | ER+ | ER+/HER2+ | 0.08 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 0 | ER+ | He+ | G2 | invasive ductal carcinoma | LN- | 66 | PgR+ | 17 | NaN |
| GSM1100072 | ER+ | ER+ | ER+ | 5.58 | 1 | 1 | 0 | 0 | 5.58 | 0 | 5.58 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 64 | PgR+ | 12 | Tamoxifen |
| GSM1100073 | ER+ | ER+ | ER+ | 5.33 | 1 | 1 | 0 | 0 | 5.33 | 0 | 5.33 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 49 | PgR+ | 15 | Tamoxifen |
| GSM1100074 | ER+ | ER+ | ER+ | 5.00 | 1 | 0 | 1 | 0 | 5.00 | 0 | 5.00 | 0 | ER+ | He- | G2 | invasive ductal carcinoma | LN- | 47 | PgR+ | 35 | ACx4 cycles |
| GSM1100075 | HER2+ | HER2+ | ER-/HER2+ | 5.46 | 1 | 0 | 1 | 0 | 1.54 | 0 | 1.54 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN- | 34 | PgR- | 40 | ACx4 cycles |
| GSM1100076 | ER+ | ER+ | ER+ | 5.46 | 1 | 1 | 0 | 0 | 5.46 | 0 | 5.46 | 0 | ER+ | He- | G1 | invasive ductal carcinoma | LN- | 45 | PgR+ | 15 | tamoxifen;goserelin |
| GSM1100077 | HER2+ | ER+ | ER+/HER2+ | 4.46 | 1 | 1 | 0 | 0 | 4.46 | 0 | 4.46 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN- | 55 | PgR+ | 20 | Tamoxifen |
| GSM1100078 | ER+ | ER+ | ER+ | 4.88 | 1 | 0 | 1 | 0 | 4.88 | 0 | 4.88 | 0 | ER+ | He- | G3 | invasive ductal carcinoma | LN+ | 47 | PgR+ | 32 | CAF |
| GSM1100079 | ER+ | ER+ | ER+ | 0.13 | 1 | 1 | 0 | 0 | NaN | 0 | 0.13 | 0 | ER+ | He- | G1 | mucinous carcinoma | LN- | 66 | PgR+ | 38 | Tamoxifen |
| GSM1100080 | HER2+ | HER2+ | ER-/HER2+ | 5.00 | 1 | 0 | 1 | 0 | 1.00 | 0 | 1.00 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN- | 55 | PgR- | 60 | ACx4 cycles |
| GSM1100081 | HER2+ | HER2+ | ER-/HER2+ | 4.33 | 1 | 0 | 1 | 0 | 4.00 | 0 | 4.00 | 0 | ER- | He+ | G3 | invasive lobular carcinoma | LN+ | 52 | PgR- | 35 | ACx4 cycles |
| GSM1100082 | HER2+ | ER+ | ER+/HER2+ | 2.25 | 1 | 1 | 0 | 1 | 2.04 | 1 | 2.04 | 1 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 74 | PgR- | 30 | Tamoxifen |
| GSM1100083 | NaN | NaN | NaN | 4.00 | 1 | 0 | 1 | 0 | 4.00 | 0 | 4.00 | 0 | ER- | NaN | G3 | invasive ductal carcinoma | LN+ | 44 | PgR- | 50 | ACx4 cycles |
| GSM1100084 | HER2+ | HER2+ | ER-/HER2+ | 4.63 | 1 | 0 | 1 | 1 | 3.96 | 1 | 3.96 | 1 | ER- | He+ | G3 | invasive ductal carcinoma | LN+ | 54 | PgR- | 20 | ACx4 cycles |
| GSM1100085 | HER2+ | ER+ | ER+/HER2+ | 5.29 | 1 | 0 | 1 | 0 | 5.25 | 0 | 5.25 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 45 | PgR+ | 25 | AC |
| GSM1100086 | HER2+ | ER+ | ER+/HER2+ | 1.96 | 1 | 0 | 1 | 0 | 1.96 | 0 | 1.96 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 58 | PgR+ | 30 | CAF |
| GSM1100087 | HER2+ | ER+ | ER+/HER2+ | 2.08 | 1 | 1 | 1 | 1 | 0.00 | 1 | 0.00 | 1 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 62 | PgR+ | 25 | Arimidex+CMFx2 cycles |
| GSM1100088 | HER2+ | HER2+ | ER-/HER2+ | 1.00 | 0 | 0 | 0 | 1 | 0.88 | 1 | 0.88 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN+ | 62 | PgR- | 35 | none |
| GSM1100089 | HER2+ | HER2+ | ER-/HER2+ | 5.08 | 1 | 0 | 1 | 0 | 5.08 | 0 | 5.08 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN- | 64 | PgR- | 30 | ACx4 cycles |
| GSM1100090 | HER2+ | HER2+ | ER-/HER2+ | 4.83 | 1 | 0 | 1 | 0 | 4.83 | 0 | 4.83 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN+ | 45 | PgR- | 20 | CAF |
| GSM1100091 | ER+ | ER+ | ER+ | 1.96 | 1 | 1 | 0 | 1 | 1.96 | 1 | 1.96 | 0 | ER+ | He- | G3 | invasive ductal carcinoma | LN+ | 80 | PgR+ | 40 | Tamoxifen |
| GSM1100092 | TNBC | TNBC | TNBC | 5.54 | 1 | 0 | 1 | 0 | 5.54 | 0 | 5.54 | 0 | ER- | He- | G3 | invasive ductal carcinoma | LN- | 41 | PgR- | 40 | ACx4 cycles |
| GSM1100093 | HER2+ | HER2+ | ER-/HER2+ | 0.38 | NaN | NaN | NaN | 1 | 0.13 | 1 | 0.13 | 1 | ER- | He+ | G3 | invasive ductal carcinoma | LN+ | 46 | PgR- | 22 | NaN |
| GSM1100094 | HER2+ | HER2+ | ER-/HER2+ | 1.38 | 1 | 0 | 1 | 1 | 1.29 | 1 | 1.29 | 1 | ER- | He+ | G3 | invasive ductal carcinoma | LN+ | 54 | PgR- | 35 | CAF |
| GSM1100095 | ER+ | ER+ | ER+ | 4.38 | 1 | 1 | 0 | 0 | 3.13 | 0 | 3.13 | 0 | ER+ | He- | G1 | invasive ductal carcinoma | LN+ | 86 | PgR+ | 21 | Tamoxifen |
| GSM1100096 | ER+ | ER+ | ER+ | 3.04 | 1 | 0 | 1 | 1 | 2.21 | 1 | 2.21 | 1 | ER+ | He- | G1 | invasive lobular carcinoma | LN+ | 29 | PgR+ | 80 | CAFx6 cycles |
| GSM1100097 | HER2+ | ER+ | ER+/HER2+ | 4.38 | 1 | 0 | 1 | 0 | 4.38 | 0 | 4.38 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 34 | PgR+ | 35 | ACx8 cycles; taxol |
| GSM1100098 | TNBC | TNBC | TNBC | 5.08 | 1 | 0 | 1 | 0 | 5.08 | 0 | 5.08 | 0 | ER- | He- | G3 | invasive ductal carcinoma | LN+ | 48 | PgR- | 30 | ACx4 cycles |
| GSM1100099 | TNBC | TNBC | TNBC | 4.25 | 1 | 0 | 1 | 0 | 4.17 | 0 | 4.17 | 0 | ER- | He- | G3 | invasive ductal carcinoma | LN- | 42 | PgR- | 22 | AC |
| GSM1100100 | TNBC | TNBC | TNBC | 0.75 | 1 | 0 | 1 | 0 | 0.75 | 0 | 0.75 | 0 | ER- | He- | G3 | invasive ductal carcinoma | LN- | 48 | PgR- | 35 | ACx4 cycles |
| GSM1100101 | HER2+ | ER+ | ER+/HER2+ | 6.29 | 1 | 1 | 1 | 0 | 6.29 | 0 | 6.29 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 52 | PgR+ | 45 | Tam+ACx4 cycles |
| GSM1100102 | ER+ | ER+ | ER+ | 5.79 | 1 | 1 | 1 | 0 | 5.58 | 0 | 5.58 | 0 | ER+ | He- | G1 | invasive ductal carcinoma | LN- | 60 | PgR+ | 15 | Tam+CMFx6 cycles |
| GSM1100103 | HER2+ | HER2+ | ER-/HER2+ | 1.46 | 1 | 0 | 1 | 1 | 0.79 | 1 | 0.79 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN+ | 51 | PgR- | 30 | ACx4 cycles |
| GSM1100104 | HER2+ | ER+ | ER+/HER2+ | 2.88 | 1 | 1 | 1 | 1 | 2.29 | 1 | 2.29 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN- | 38 | PgR- | 36 | Tam+ACx4 cycles |
| GSM1100105 | HER2+ | HER2+ | ER-/HER2+ | 4.00 | NaN | NaN | NaN | 0 | 4.00 | 0 | 4.00 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN- | 42 | PgR- | 23 | NaN |
| GSM1100106 | ER+ | ER+ | ER+ | NaN | 1 | 1 | 0 | NaN | NaN | NaN | NaN | NaN | ER+ | He- | G1 | papillary carcinoma | LN- | 81 | PgR+ | 40 | Tamoxifen |
| GSM1100107 | ER+ | ER+ | ER+ | 4.33 | 1 | 1 | 0 | 0 | 3.50 | 0 | 3.50 | 0 | ER+ | He- | G1 | invasive ductal carcinoma | LN- | 77 | PgR+ | 40 | Tamoxifen |
| GSM1100108 | TNBC | TNBC | TNBC | 6.50 | 0 | 0 | 0 | 0 | 1.17 | 0 | 1.17 | 0 | ER- | He- | G3 | medullary carcinoma | LN- | 42 | PgR- | 20 | none |
| GSM1100109 | ER+ | ER+ | ER+ | 5.88 | 1 | 0 | 1 | 0 | 5.88 | 0 | 5.88 | 0 | ER+ | He- | G3 | invasive ductal carcinoma | LN+ | 61 | PgR- | 25 | CMF |
| GSM1100110 | HER2+ | HER2+ | ER-/HER2+ | 5.71 | 1 | 0 | 1 | 0 | 5.71 | 0 | 5.71 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN- | 48 | PgR- | 32 | ACx4 cycles |
| GSM1100111 | HER2+ | HER2+ | ER-/HER2+ | 5.83 | 1 | 0 | 1 | 0 | 5.83 | 0 | 5.83 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN+ | 61 | PgR- | 15 | CAFx6 cycles |
| GSM1100112 | ER+ | ER+ | ER+ | 6.17 | 1 | 1 | 1 | 0 | 6.17 | 0 | 6.17 | 0 | ER+ | He- | G3 | invasive ductal carcinoma | LN- | 36 | PgR+ | 25 | Tam+CMFx6 cycles |
| GSM1100113 | HER2+ | HER2+ | ER-/HER2+ | 5.58 | 1 | 0 | 1 | 1 | 1.92 | 0 | 1.33 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN- | 51 | PgR- | 27 | ACx4 cycles |
| GSM1100114 | TNBC | TNBC | TNBC | 5.83 | 1 | 0 | 1 | 0 | 5.83 | 0 | 5.83 | 0 | ER- | He- | G3 | invasive ductal carcinoma | LN- | 46 | PgR- | 25 | ACx4 cycles |
| GSM1100115 | HER2+ | HER2+ | ER-/HER2+ | 5.83 | 1 | 0 | 1 | 0 | 5.83 | 0 | 5.83 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN- | 48 | PgR- | 35 | ACx4 cycles |
| GSM1100116 | ER+ | ER+ | ER+ | 5.79 | 1 | 1 | 1 | 0 | 5.79 | 0 | 5.79 | 0 | ER+ | He- | G3 | invasive ductal carcinoma | LN- | 51 | PgR- | 18 | Tam+CMFx6 cycles |
| GSM1100117 | HER2+ | HER2+ | ER-/HER2+ | 5.88 | 1 | 0 | 1 | 0 | 5.88 | 0 | 5.88 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN- | 47 | PgR- | 21 | ACx4 cycles |
| GSM1100118 | HER2+ | ER+ | ER+/HER2+ | 5.92 | 1 | 1 | 1 | 0 | 5.92 | 0 | 5.92 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 58 | PgR+ | 51 | Tam+ACx4 cycles |
| GSM1100119 | HER2+ | ER+ | ER+/HER2+ | 5.58 | 1 | 1 | 1 | 0 | 5.58 | 0 | 5.58 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN- | 38 | PgR+ | 38 | Tam+ACx4 cycles |
| GSM1100120 | ER+ | ER+ | ER+ | 4.54 | 1 | 0 | 1 | 0 | 4.54 | 0 | 4.54 | 0 | ER+ | He- | G3 | invasive ductal carcinoma | LN+ | 47 | PgR+ | 30 | CAF |
| GSM1100121 | HER2+ | ER+ | ER+/HER2+ | 5.21 | 1 | 1 | 0 | 0 | 5.21 | 0 | 5.21 | 0 | ER+ | He+ | G3 | medullary carcinoma | LN- | 64 | PgR+ | 50 | Tamoxifen |
| GSM1100122 | HER2+ | HER2+ | ER-/HER2+ | 5.75 | 1 | 1 | 1 | 1 | 3.83 | 1 | 3.83 | 0 | ER- | He+ | G3 | invasive ductal carcinoma | LN+ | 50 | PgR+ | 16 | Tam+ACx4 cycles |
| GSM1100123 | ER+ | ER+ | ER+ | 5.17 | 1 | 1 | 0 | 0 | 5.17 | 0 | 5.17 | 0 | ER+ | He- | G1 | invasive lobular carcinoma | LN- | 52 | PgR+ | 20 | Tamoxifen |
| GSM1100124 | HER2+ | ER+ | ER+/HER2+ | 4.92 | 1 | 1 | 0 | 0 | 4.92 | 0 | 4.92 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 67 | PgR- | 25 | Tamoxifen |
| GSM1100125 | HER2+ | ER+ | ER+/HER2+ | 2.00 | 1 | 1 | 1 | 1 | 2.00 | 1 | 2.00 | 0 | ER+ | He+ | G3 | invasive ductal carcinoma | LN+ | 38 | PgR+ | 40 | Tam+AC |
| GSM1100126 | ER+ | ER+ | ER+ | 0.83 | 1 | 1 | 0 | 0 | 0.83 | 0 | 0.83 | 0 | ER+ | He- | G3 | invasive ductal carcinoma | LN- | 84 | PgR+ | 28 | Tamoxifen |
| GSM1100127 | NaN | NaN | NaN | 4.67 | 0 | 0 | 0 | 0 | 4.67 | 0 | 4.67 | 0 | NaN | NaN | G1 | invasive ductal carcinoma and papillary carcinoma | LN- | 55 | NaN | 25 | none |
| GSM1100128 | ER+ | ER+ | ER+ | 2.67 | 1 | 1 | 1 | 0 | 2.67 | 0 | 2.67 | 0 | ER+ | He- | G1 | invasive ductal carcinoma | LN+ | 43 | PgR+ | 24 | Tam+ACx4 cycles |
| GSM1100129 | ER+ | ER+ | ER+ | 4.38 | 1 | 1 | 0 | 0 | 4.38 | 0 | 4.38 | 0 | ER+ | He- | G3 | invasive ductal carcinoma | LN- | 62 | PgR+ | 20 | Tamoxifen |
| GSM1100130 | ER+ | ER+ | ER+ | 4.83 | NaN | NaN | NaN | 0 | 4.83 | 0 | 4.83 | 0 | ER+ | He- | G1 | invasive ductal carcinoma | LN+ | 59 | PgR+ | 60 | NaN |
| GSM1100131 | ER+ | ER+ | ER+ | 4.33 | 1 | 1 | 1 | 0 | 4.33 | 0 | 4.33 | 0 | ER+ | NaN | G3 | invasive ductal carcinoma | LN+ | 53 | PgR+ | 35 | Tam+CMFx6 cycles |
| GSM1100132 | HER2+ | ER+ | ER+/HER2+ | 3.44931506849315 | 1 | 1 | 0 | NaN | NaN | 1 | 3.05 | 1 | ER+ | He+ | G2 | NaN | LN- | 63 | NaN | 30 | Tamoxifen |
| GSM1100133 | HER2+ | ER+ | ER+/HER2+ | 2.12602739726027 | 1 | 1 | 1 | NaN | NaN | 1 | 1.39 | 1 | ER+ | He+ | G3 | NaN | LN- | 47 | PgR+ | 28 | CMFx6; Tamoxifen |
| GSM1100134 | HER2+ | HER2+ | ER-/HER2+ | 3.07945205479452 | 1 | 1 | 0 | NaN | NaN | 1 | 0.65 | 1 | ER- | He+ | G3 | NaN | LN- | 59 | PgR- | 25 | Tamoxifen |
| GSM1100135 | TNBC | TNBC | TNBC | 4.19452054794521 | 1 | 1 | 0 | NaN | NaN | 1 | 4.18 | 1 | ER- | He- | G3 | NaN | LN- | 66 | PgR- | 21 | Tamoxifen |
| GSM1100136 | ER+ | ER+ | ER+ | 6.17260273972603 | 1 | 1 | 0 | NaN | NaN | 1 | 4.51 | 1 | ER+ | He- | G3 | NaN | LN- | 68 | PgR+ | 17 | Tamoxifen |
| GSM1100137 | HER2+ | ER+ | ER+/HER2+ | 5.03561643835616 | 1 | 1 | 0 | NaN | NaN | 1 | 0.25 | 1 | ER+ | He+ | NaN | NaN | LN- | 57 | PgR+ | 85 | Tamoxifen |
| GSM1100138 | ER+ | ER+ | ER+ | 2.75342465753425 | 1 | 1 | 1 | NaN | NaN | 1 | 1.35 | 1 | ER+ | He- | G3 | NaN | LN- | 38 | PgR- | 32 | ECx4; Tamoxifen |
| GSM1100139 | ER+ | ER+ | ER+ | 4.92876712328767 | 1 | 1 | 0 | NaN | NaN | 1 | 2.21 | 1 | ER+ | He- | G3 | NaN | LN- | 63 | PgR+ | 46 | Tamoxifen |
| GSM1100140 | TNBC | TNBC | TNBC | 4.62191780821918 | 1 | 0 | 1 | NaN | NaN | 1 | 3.80 | 1 | ER- | He- | G3 | NaN | LN- | 73 | PgR- | 34 | ACx3/CMFx1 |
| GSM1100141 | HER2+ | ER+ | ER+/HER2+ | 0.991780821917808 | 1 | 1 | 0 | NaN | NaN | 1 | 0.76 | 1 | ER+ | He+ | G3 | NaN | LN- | 70 | PgR+ | 35 | Tamoxifen |
| GSM1100142 | ER+ | ER+ | ER+ | 2.18904109589041 | 1 | 1 | 1 | NaN | NaN | 0 | 2.18 | 0 | ER+ | He- | G1 | NaN | LN- | 46 | PgR- | 10 | Tamoxifen+Zoledronic acid |
| GSM1100143 | TNBC | TNBC | TNBC | 7.07945205479452 | 1 | 1 | 1 | NaN | NaN | 1 | 2.42 | 0 | ER- | He- | G2 | NaN | LN- | 36 | PgR- | 13 | Tamoxifen+Zoledronic acid |
| GSM1100144 | ER+ | ER+ | ER+ | 8.02191780821918 | 1 | 0 | 1 | NaN | NaN | 1 | 6.15 | 0 | ER+ | He- | G1 | NaN | LN- | 54 | PgR- | 55 | ACx4 |
| GSM1100145 | ER+ | ER+ | ER+ | 6.75068493150685 | 1 | 1 | 1 | NaN | NaN | 1 | 3.65 | 0 | ER+ | He- | G3 | NaN | LN- | 60 | PgR+ | 40 | CMFx2; Tamoxifen |
| GSM1100146 | HER2+ | ER+ | ER+/HER2+ | 5.16438356164384 | 1 | 1 | 0 | NaN | NaN | 1 | 3.30 | 0 | ER+ | He+ | G3 | NaN | LN- | 72 | PgR+ | 37 | Arimidex/Tamoxifen |
| GSM1100147 | TNBC | TNBC | TNBC | 7.82191780821918 | 1 | 1 | 0 | NaN | NaN | 0 | 7.82 | 0 | ER- | He- | G2 | NaN | LN- | 54 | PgR- | 10 | Tamoxifen |
| GSM1100148 | HER2+ | ER+ | ER+/HER2+ | 7.85479452054795 | 1 | 1 | 1 | NaN | NaN | 0 | 7.85 | 0 | ER+ | He+ | G2 | NaN | LN- | 48 | NaN | 12 | Tamoxifen+Zoledronic acid |
| GSM1100149 | ER+ | ER+ | ER+ | 7.30684931506849 | 1 | 1 | 0 | NaN | NaN | 0 | 7.31 | 0 | ER+ | He- | G3 | NaN | LN- | 55 | PgR+ | 18 | Tamoxifen |
| GSM1100150 | HER2+ | ER+ | ER+/HER2+ | 7.57260273972603 | 1 | 1 | 0 | NaN | NaN | 0 | 7.57 | 0 | ER+ | He+ | G2 | NaN | LN- | 81 | PgR- | 20 | Tamoxifen |
| GSM1100151 | HER2+ | HER2+ | ER-/HER2+ | 6.01917808219178 | 1 | 1 | 1 | NaN | NaN | 0 | 6.02 | 0 | ER- | He+ | G2 | NaN | LN- | 52 | PgR- | 20 | ACx4; Tamoxifen |
| GSM1100152 | HER2+ | ER+ | ER+/HER2+ | 6.17534246575342 | 1 | 1 | 0 | NaN | NaN | 0 | 6.18 | 0 | ER+ | He+ | G2 | NaN | LN- | 77 | PgR+ | 15 | Tamoxifen |
| GSM1100153 | HER2+ | ER+ | ER+/HER2+ | 6.65205479452055 | 1 | 1 | 0 | NaN | NaN | 0 | 6.65 | 0 | ER+ | He+ | G2 | NaN | LN- | 70 | PgR- | 35 | Tamoxifen |
| GSM1100154 | TNBC | TNBC | TNBC | 6.61369863013699 | 1 | 1 | 1 | NaN | NaN | 0 | 6.61 | 0 | ER- | He- | G3 | NaN | LN- | 67 | PgR- | 40 | ACx6; Tamoxifen |
| GSM1100155 | HER2+ | ER+ | ER+/HER2+ | 6.12876712328767 | 1 | 1 | 0 | NaN | NaN | 0 | 6.13 | 0 | ER+ | He+ | G3 | NaN | LN- | 62 | PgR+ | 27 | Tamoxifen |
| GSM1100156 | ER+ | ER+ | ER+ | 5.93698630136986 | 1 | 1 | 0 | NaN | NaN | 0 | 5.94 | 0 | ER+ | He- | G1 | NaN | LN- | 66 | PgR+ | 27 | Tamoxifen |
| GSM1100157 | HER2+ | ER+ | ER+/HER2+ | 3.11506849315069 | 1 | 1 | 0 | NaN | NaN | 0 | 3.12 | 0 | ER+ | He+ | G1 | NaN | LN- | 57 | PgR- | 20 | Tamoxifen |
| GSM1100158 | NaN | NaN | NaN | 2.57260273972603 | 1 | 1 | 1 | NaN | NaN | 0 | 2.57 | 0 | NaN | NaN | G3 | NaN | LN- | 46 | NaN | 32 | CMFx6; Tamoxifen |
| GSM1100159 | TNBC | TNBC | TNBC | 6.18630136986301 | NaN | NaN | NaN | NaN | NaN | 0 | 6.19 | 0 | ER- | He- | NaN | NaN | LN- | 73 | PgR- | 38 | NaN |
| GSM1100160 | ER+ | ER+ | ER+ | 6.69315068493151 | 1 | 0 | 1 | NaN | NaN | 0 | 6.69 | 0 | ER+ | He- | G2 | NaN | LN- | 42 | PgR+ | 14 | CMFx6 |
| GSM1100161 | ER+ | ER+ | ER+ | 5.52328767123288 | 1 | 1 | 0 | NaN | NaN | 0 | 5.52 | 0 | ER+ | He- | G3 | NaN | LN- | 53 | PgR+ | 19 | Tamoxifen |
| GSM1100162 | ER+ | ER+ | ER+ | 5.10958904109589 | 1 | 1 | 1 | NaN | NaN | 0 | 5.11 | 0 | ER+ | He- | G3 | NaN | LN- | 60 | PgR+ | 20 | ACx4; Arimidex/Tamoxifen |
| GSM1100163 | TNBC | TNBC | TNBC | 5.56712328767123 | 1 | 1 | 1 | NaN | NaN | 0 | 5.57 | 0 | ER- | He- | G3 | NaN | LN- | 61 | PgR- | 14 | CMFx6; Arimidex/Tamoxifen |
| GSM1100164 | NaN | NaN | NaN | 6.25753424657534 | 1 | 0 | 1 | NaN | NaN | 0 | 6.26 | 0 | ER- | NaN | G3 | NaN | LN- | 59 | PgR- | 45 | ACx4 |
| GSM1100165 | ER+ | ER+ | ER+ | 5.13424657534247 | 1 | 1 | 0 | NaN | NaN | 0 | 5.13 | 0 | ER+ | He- | G2 | NaN | LN- | 70 | PgR- | 20 | Tamoxifen |
| GSM1100166 | ER+ | ER+ | ER+ | 4.64383561643836 | 1 | 0 | 1 | NaN | NaN | 0 | 4.64 | 0 | ER+ | He- | G2 | NaN | LN- | 45 | PgR+ | 20 | CMFx6 |
| GSM1100167 | HER2+ | HER2+ | ER-/HER2+ | 5.00821917808219 | 1 | 0 | 1 | NaN | NaN | 0 | 5.01 | 0 | ER- | He+ | G3 | NaN | LN- | 48 | PgR- | 60 | CMFx6 |
| GSM1100168 | HER2+ | ER+ | ER+/HER2+ | 4.56164383561644 | 1 | 1 | 0 | NaN | NaN | 0 | 4.56 | 0 | ER+ | He+ | G2 | NaN | LN- | 45 | PgR+ | 30 | Tamoxifen |
| GSM1100169 | TNBC | TNBC | TNBC | 4.95890410958904 | 1 | 1 | 1 | NaN | NaN | 0 | 4.96 | 0 | ER- | He- | G3 | NaN | LN- | 46 | PgR- | 27 | CMFx6; Tamoxifen |
| GSM1100170 | HER2+ | ER+ | ER+/HER2+ | 3.92602739726027 | 1 | 1 | 0 | NaN | NaN | 0 | 3.93 | 0 | ER+ | He+ | G1 | NaN | LN- | 56 | PgR+ | 30 | Tamoxifen |
| GSM1100171 | ER+ | ER+ | ER+ | 4.50958904109589 | 1 | 1 | 0 | NaN | NaN | 0 | 4.51 | 0 | ER+ | He- | G2 | NaN | LN- | 72 | PgR- | 20 | Tamoxifen |
| GSM1100172 | TNBC | TNBC | TNBC | 1.66027397260274 | 1 | 0 | 1 | NaN | NaN | 0 | 1.66 | 0 | ER- | He- | G3 | NaN | LN- | 50 | PgR- | 29 | CMFx6 |
| GSM1100173 | NaN | NaN | NaN | NaN | 0 | 0 | 0 | 1 | 7.15 | 1 | 7.151 | NaN | ER- | NaN | NaN | NaN | LN- | 67 | NaN | 10 | none |
| GSM1100174 | NaN | NaN | NaN | NaN | 0 | 0 | 0 | 1 | 10.61 | 0 | 10.614 | NaN | ER- | NaN | G2 | NaN | LN- | 37 | NaN | 23 | none |
| GSM1100175 | ER+ | ER+ | ER+ | NaN | 0 | 0 | 0 | 0 | 9.42 | 0 | 9.419 | NaN | ER+ | NaN | G1 | NaN | LN- | 43 | NaN | 21 | none |